157 related articles for article (PubMed ID: 29984527)
21. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
[TBL] [Abstract][Full Text] [Related]
22. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
23. Novel pyrrolopyridinone derivatives as anticancer inhibitors towards Cdc7: QSAR studies based on dockings by solvation score approach.
Wu X; Zeng H; Zhu X; Ma Q; Hou Y; Wu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):323-34. PubMed ID: 23933111
[TBL] [Abstract][Full Text] [Related]
24. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
25. High levels of Cdc7 and Dbf4 proteins can arrest cell-cycle progression.
Guo B; Romero J; Kim BJ; Lee H
Eur J Cell Biol; 2005 Dec; 84(12):927-38. PubMed ID: 16325502
[TBL] [Abstract][Full Text] [Related]
26. Cdc7 is an active kinase in human cancer cells undergoing replication stress.
Tenca P; Brotherton D; Montagnoli A; Rainoldi S; Albanese C; Santocanale C
J Biol Chem; 2007 Jan; 282(1):208-15. PubMed ID: 17062569
[TBL] [Abstract][Full Text] [Related]
27. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanism of activation of human Cdc7 kinase: bipartite interaction with Dbf4/activator of S phase kinase (ASK) activation subunit stimulates ATP binding and substrate recognition.
Kitamura R; Fukatsu R; Kakusho N; Cho YS; Taniyama C; Yamazaki S; Toh GT; Yanagi K; Arai N; Chang HJ; Masai H
J Biol Chem; 2011 Jul; 286(26):23031-43. PubMed ID: 21536671
[TBL] [Abstract][Full Text] [Related]
29. Cdc7 kinase - a new target for drug development.
Swords R; Mahalingam D; O'Dwyer M; Santocanale C; Kelly K; Carew J; Giles F
Eur J Cancer; 2010 Jan; 46(1):33-40. PubMed ID: 19815406
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
Irie T; Asami T; Sawa A; Uno Y; Hanada M; Taniyama C; Funakoshi Y; Masai H; Sawa M
Eur J Med Chem; 2017 Apr; 130():406-418. PubMed ID: 28279847
[TBL] [Abstract][Full Text] [Related]
31. Cdc7 as a potential new target for cancer therapy.
Ito S; Taniyami C; Arai N; Masai H
Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
[TBL] [Abstract][Full Text] [Related]
32. Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents.
AlAjmi MF; Rehman MT; Hussain A; Rather GM
Int J Biol Macromol; 2018 Sep; 116():173-181. PubMed ID: 29738867
[TBL] [Abstract][Full Text] [Related]
33. Studies of Interaction Mechanism between Pyrido [3,4-
Xing C; Zhou X; Chen C; Sun W; Zheng Q; Liang D
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443663
[TBL] [Abstract][Full Text] [Related]
34. Pharmacophore modeling, molecular docking and molecular dynamics simulations toward identifying lead compounds for Chk1.
Li Y; Peng J; Zhou Y; Li P; Li Y; Liu X; Siddique AN; Zhang L; Zuo Z
Comput Biol Chem; 2018 Oct; 76():53-60. PubMed ID: 29940486
[TBL] [Abstract][Full Text] [Related]
35. An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.
Meirson T; Samson AO; Gil-Henn H
Drug Des Devel Ther; 2017; 11():1535-1557. PubMed ID: 28572720
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-
Kurasawa O; Miyazaki T; Homma M; Oguro Y; Imada T; Uchiyama N; Iwai K; Yamamoto Y; Ohori M; Hara H; Sugimoto H; Iwata K; Skene R; Hoffman I; Ohashi A; Nomura T; Cho N
J Med Chem; 2020 Feb; 63(3):1084-1104. PubMed ID: 31895562
[TBL] [Abstract][Full Text] [Related]
37. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
Harrington PE; Bourbeau MP; Fotsch C; Frohn M; Pickrell AJ; Reichelt A; Sham K; Siegmund AC; Bailis JM; Bush T; Escobar S; Hickman D; Heller S; Hsieh F; Orf JN; Rong M; San Miguel T; Tan H; Zalameda L; Allen JG
Bioorg Med Chem Lett; 2013 Dec; 23(23):6396-400. PubMed ID: 24120542
[TBL] [Abstract][Full Text] [Related]
38. Covalent docking of large libraries for the discovery of chemical probes.
London N; Miller RM; Krishnan S; Uchida K; Irwin JJ; Eidam O; Gibold L; Cimermančič P; Bonnet R; Shoichet BK; Taunton J
Nat Chem Biol; 2014 Dec; 10(12):1066-72. PubMed ID: 25344815
[TBL] [Abstract][Full Text] [Related]
39. Localization of Cdc7 Protein Kinase During DNA Replication in
Rossbach D; Bryan DS; Hesselberth JR; Sclafani R
G3 (Bethesda); 2017 Nov; 7(11):3757-3774. PubMed ID: 28924058
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
